ADPKD Clinical Trial
Official title:
A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease
The goal of the study was to compare and evaluate safety and efficacy of tesevatinib 50 milligrams (mg) versus placebo in participants with autosomal dominant polycystic kidney disease (ADPKD).
Safety and efficacy of 50 mg tesevatinib in comparison to placebo in participants with ADPKD was assessed. The primary purpose of this study was focused on evaluating the change from Baseline in height-adjusted total kidney volume (htTKV) as measured by magnetic resonance imaging (MRI) at Months 12, 18, and 24, and 30 days post-dose in participants with ADPKD treated with tesevatinib or placebo. If eligible for the study participation, participants were randomly assigned to either investigational treatment group or placebo group. Treatment group received 50 mg tesevatinib once daily for 24 months and control group received the placebo once daily for 24 months. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310319 -
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
|
N/A | |
Recruiting |
NCT03596957 -
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 4 | |
Terminated |
NCT04064346 -
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
Recruiting |
NCT05500157 -
Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts
|
N/A | |
Recruiting |
NCT04111692 -
A Prospective Observational Study of Foam Sclerotherapy .
|
||
Recruiting |
NCT04907799 -
Daily Caloric Restriction in ADPKD
|
N/A | |
Completed |
NCT05401409 -
Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Terminated |
NCT03918447 -
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
|
Phase 3 | |
Not yet recruiting |
NCT06391450 -
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
|
Phase 4 | |
Terminated |
NCT03749447 -
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
|
Phase 3 | |
Recruiting |
NCT05228574 -
Treatment of Vascular Stiffness in ADPKD
|
Phase 4 | |
Completed |
NCT04908462 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03858439 -
Dietary Intervention in ADPKD on Tolvaptan
|
N/A | |
Recruiting |
NCT05478083 -
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
|
Phase 2 | |
Completed |
NCT03102632 -
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Recruiting |
NCT05996731 -
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
|
N/A | |
Recruiting |
NCT06193616 -
Outcome of ADPKD With Octreotide LAR
|
||
Completed |
NCT05646420 -
Thyroid Hormones in ADPKD
|
N/A | |
Completed |
NCT03366337 -
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
|
Phase 2 | |
Active, not recruiting |
NCT03273413 -
Statin Therapy in Patients With Early Stage ADPKD
|
Phase 4 |